Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:
8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.
In cohort 1 (dose=6mg/m^2) three patients were enrolled.
The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third
The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
